NCT03437785 is a Phase 2 clinical trial of CKD-495 75mg in Gastritis, sponsored by Chong Kun Dang Pharmaceutical.

Who is sponsoring NCT03437785?

NCT03437785 is sponsored by Chong Kun Dang Pharmaceutical.

What drugs are being tested in NCT03437785?

Interventions in NCT03437785: CKD-495 75mg, CKD-495 150mg, Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg, Rebamipide 100mg, Placebo of the CKD-495 75mg, Placebo of the CKD-495 150mg, Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg, Placebo of the Rebamipide 100mg.

Is NCT03437785 still recruiting?

NCT03437785 is currently completed. Last updated 31 October 2018.

Last reviewed 2018-10-31 · How we verify

NCT03437785

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Trial to Evaluate the Efficacy and Safety of CKD-495 Tablet

Completed Phase 2 Last updated 31 October 2018

What this trial tests

Phase 2 trial testing CKD-495 75mg in Gastritis in 250 participants. Completed in 12 October 2018.

Timeline

16 January 2018

Primary endpoint
12 October 2018

12 October 2018

Quick facts

Lead sponsor	Chong Kun Dang Pharmaceutical
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	250
Start date	16 January 2018
Primary completion	12 October 2018
Estimated completion	12 October 2018
Sites	16 locations across South Korea

Drugs / interventions tested

CKD-495 75mg — full drug profile →
CKD-495 150mg — full drug profile →
Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg
Rebamipide 100mg
Placebo of the CKD-495 75mg — full drug profile →
Placebo of the CKD-495 150mg
Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg — full drug profile →
Placebo of the Rebamipide 100mg — full drug profile →

Conditions studied

Gastritis — all drugs for Gastritis →

Sponsor

Chong Kun Dang Pharmaceutical — full company profile →

Who can join

19 and older, any sex, with Gastritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To Evaluate the Efficacy and Safety of CKD-495

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Efficacy and safety of CKD-495 in acute and chronic gastritis: A Phase III superiority clinical trial.
Seo SY, Lee ST, Kim SK, Chun HJ, et al · · 2023 · cited 4× · PMID 38065906 · DOI 10.1097/md.0000000000035926
A Phase 2, Multi-Center, Randomized, Double-Blind, Parallel-Group Trial to Evaluate the Efficacy and Safety of CKD-495 in Patients With Acute and Chronic Gastritis.
Park SH, Lee OY, Lee YC, Park KS, et al · · 2025 · cited 3× · PMID 40255536 · DOI 10.1155/cjgh/2702089
Exploring the Therapeutic Potential of <i>Artemisia</i> and <i>Salvia</i> Genera in Cancer, Diabetes, and Cardiovascular Diseases: A Short Review of Clinical Evidence.
Tavares WR, Seca AML, Barreto MC. · · 2025 · cited 3× · PMID 39941696 · DOI 10.3390/jcm14031028

Verify or expand the search:

Other trials of CKD-495 75mg

Trials testing the same drug.

NCT04255589 — A Clinical Trial to Evaluate the Efficacy and Safety of CKD-495 · Phase 3 · completed

Other recruiting trials for Gastritis

Currently open trials in the same condition.

NCT07032961 — A Cohort Study of Mobile Capsule Gastroscopy for Gastric Pathologies Screening · recruiting
NCT06948487 — Efficacy and Safety of FEXUCLUE Tab. In Patients With Acute or Chronic Gastritis · recruiting
NCT06848400 — Capsule Gastric Endoscopy for Gastric Disease Screening in Simulated Home Scenarios · NA · recruiting

Other Chong Kun Dang Pharmaceutical trials

Trials by the same sponsor.

NCT07404735 — A Clinical Trial to Compare and Evaluate Evaluate the Pharmacokinetics and Safety of CKD-846 · Phase 1 · not yet recruiting
NCT07358156 — A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and E · Phase 1 · recruiting
NCT07258745 — Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-appro · Phase 1 · recruiting
NCT07304726 — Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.25/12.5/1000mg in Healthy Volunteers · Phase 1 · completed
NCT07304700 — Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/10/1000mg in Healthy Volunteers · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03437785 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chong Kun Dang Pharmaceutical
Last refreshed: 31 October 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03437785.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing